Neurol. praxi. 2016;17(3):95-99 | DOI: 10.36290/neu.2016.033

Cardiac function in hypertensive patients with metabolic syndrome and microalbuminuria

MUDr. Jiří Piťha

Centrum myasthenia gravis, Neurologická klinika 1. LF UK a VFN, Centrum klinických neurověd

Neurologické oddělení KZ a.s. - Nemocnice Teplice o. z., Teplice

Myasthenia gravis is an autoimmune disease affecting the postsynaptic part of neuromuscular junction. The disease can manifest

in early or late age, weakening of muscles is generalized, or only affects the extraocular muscles. Pathological changes in the thymus

consist card follicular hyperplasia or atrophy. Paraneoplastic form is associated with thymoma. The 80% can be demonstrated

antibodies against acetylcholine receptor or muscle specific tyrosine kinase. Although in its course highly variable disease, we can,

according to its course, particularly in the initial stages and to predict the prognosis of the disease in a particular patient is trying

to establish an individualized treatment, which would lead to the achievement of clinical remission and the best possible quality

of life. Bad prognostic factors include the detection of antibodies to muscle-specific tyrosine kinase, higher age manifestations,

associated comorbidities, association with thymoma, fulminant development myasthenic crisis during the first year of the disease

and delayed assesment of diagnosis.

Keywords: myasthenia gravis, clinical aspects, prognosis, treatment strategies, individualized therapy

Published: August 1, 2016  Show citation